Navigation Links
Veracyte, Inc. Announces Third Quarter 2013 Financial Results
Date:11/25/2013

the value of expanding the test to this patient population; the estimated size of the global market for Afirma; and the company's intent to expand its molecular cytology business into other clinical areas. Forward-looking statements involve risks and uncertainties which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our limited operating history and history of losses; our ability to increase usage of and reimbursement for Afirma; our dependence on a few payers for a significant portion of our revenue; the complexity, time and expense associated with billing and collecting from payers for our test; laws and regulations applicable to our business, including potential regulation by the FDA; our dependence on strategic relationships; our ability to develop and commercialize new products and the timing of commercialization; the outcome of clinical studies; the applicability of clinical results to actual outcomes; our ability to compete; our ability to expand into international markets; our ability to obtain capital when needed; and other risks detailed under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.VERACYTE, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited)(In thousands, except share and per share amounts)Three Months Ended Nine Months Ended September 30,September 30,September 30,September 30,2013201220132012Revenue 

$
5,594$
3,224$
5,046$
7,171Operating expenses:Cost of revenue 

3,1321,9849,1364,984Research and development 

2,0281,7295,9404,887Selling and marketing 

3,2912,3478,6095,392General and adm
'/>"/>

SOURCE Veracyte
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Veracyte, Inc. to Announce Third Quarter 2013 Financial Results and Host Conference Call on Monday, November 25, 2013
2. Veracyte, Inc. Announces Pricing of Initial Public Offering
3. Orexigen Announces Successful Interim Analysis of Contrave Light Study
4. Golden Meditech Announces 2013 / 2014 Interim Results
5. iHealth Announces Results of AHA Walking Challenge
6. Unilife Announces Results of 2013 Annual General Meeting
7. Hanger Announces Appointment of Christopher B. Begley to Board of Directors
8. CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2013
9. Array BioPharma Announces Management Team Change
10. Hill-Rom Holdings, Inc. Announces First Quarter 2014 Dividend
11. Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing Bringing Total Commitment To $60 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Maine, July 25, 2014  IDEXX Laboratories, Inc. (NASDAQ: ... the second quarter of 2014 increased 11% versus the ... 1 for the second quarter of 2014 versus ... for changes in distributor inventory 2 . Earnings per ... 2014 increased 11% from the prior year period to ...
(Date:7/25/2014)...  Semler Scientific, Inc. (Nasdaq: SMLR ... that develops patented products that assist healthcare providers ... reported financial results for the second quarter and ... "The second quarter of 2014 continued to ... , M.D., chief executive officer of Semler.  "We ...
(Date:7/25/2014)... CHICAGO, Ill., July 25, 2014 NOT ... DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE ... LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ... ended June 30, 2014. "This was another ... earnings per share above our original guidance and announced plans ...
Breaking Medicine Technology:IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33IDEXX Laboratories Announces Second Quarter Results 34Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3
... ARBOR, Mich., Sept. 17 Terumo Heart, ... European Launch Symposium at the European,Association of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO ) (Logo: ... of the European Clinical Trial results for ...
... to enter Phase 2 clinical development, PRINCETON, ... an innovator in the discovery and development of ... a Phase 2a,clinical study of PS433540, the company,s ... and endothelin receptor antagonist,(DARA) that is being developed ...
Cached Medicine Technology:Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
(Date:7/26/2014)... WA (PRWEB) July 26, 2014 “Healthy teeth ... in keeping those pearly whites shining,” says Community Health Center ... Teeth Healthy ." , They believe that an integration of ... people healthy and well. Because of this, they encourage regular ... also with dentist . , “Children and adults will ...
(Date:7/26/2014)... July 26, 2014 Multiple sclerosis ... disseminata, is an inflammatory disease in which the ... and spinal cord are damaged. This damage disrupts ... to communicate, resulting in a wide range of ... psychiatric problems. Multiple sclerosis takes several forms, with ...
(Date:7/26/2014)... OH (PRWEB) July 26, 2014 The U.S. ... guidelines list that includes a new medication guide for AndroGel ... a serious side-effect of taking the topical low testosterone medication, ... that AbbVie Inc., the makers of the low testosterone theapy ... symptoms of pain, swelling or redness as signs of a ...
(Date:7/26/2014)... Louisville, Kentucky (PRWEB) July 26, 2014 ... concussions on the playing field; however, concussions ... on-the-job injuries. The occupations with the highest risk ... workers ,     Firefighters ,     Police officers ... dock workers ,     Delivery personnel ...
(Date:7/26/2014)... According to the Banish My Bumps ... comprehensive guide that covers detailed instructions on how to ... need of any medication. , Vkool reveals in ... safe remedies for relieving symptoms of keratosis pilaris quickly. ...     How to treat children's keratosis pilaris , ...
Breaking Medicine News(10 mins):Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 2Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 3Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3
... oral use of RU-486,s companion drug misoprostol is safe, but ... use of a drug given with RU-486 to terminate a ... infections seen in women taking the drugs since 2000, a ... drug misoprostol is FDA-approved to be taken by mouth along ...
... awarded to IDC in ... Pakistan, ... the global leader in the rapidly growing market for,digital radiography, today announced ... Pakistan to install the X-Series 2200,digital radiography (DR) systems in eight A-Class ...
... Clinica - the world,s leading news,service for the medical ... London,s Houses of Parliament have been at risk of ... during the,last three years. This news comes despite warnings ... Parliamentary assurances that the material,discovered in 2005 was safely ...
... Plan honored for service, strategic excellence by federal program, ... today,that the Blue Cross and Blue Shield Association has ... as well as to eight other,affiliated Blue plans., ... 2007 Best of,Blue FEP Plan Excellence winners at its ...
... showed similarities between lesbians, straight men , , MONDAY, June 16 ... remarkable similarities between the brains of gay men and straight ... For example, the brains of straight men and of gay ... the right hemisphere larger than the left, say the Swedish ...
... noninvasive molecular imaging technology, a method has been developed ... cells (MSCs) in the tumors of living organisms, according ... could lead to major advances in the use of ... cancer therapies are still in the early stages of ...
Cached Medicine News:Health News:Abortion drug's off-label use may have led to deaths 2Health News:Abortion drug's off-label use may have led to deaths 3Health News:IDC implements DR systems in eight A-Class military hospitals in Pakistan 2Health News:IDC implements DR systems in eight A-Class military hospitals in Pakistan 3Health News:Palace of Westminster Asbestos Problem Ignored 2Health News:Gay Men, Straight Women Have Similar Brains 2Health News:Gay Men, Straight Women Have Similar Brains 3Health News:Ability to track stem cells in tumors could advance cancer treatments 2Health News:Ability to track stem cells in tumors could advance cancer treatments 3
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the quantitative colorimetric determination of AST (SGOT) in serum....
For the quantitative determination of aspartate aminotransferase in serum. Optimized IFCC procedure without P-5'-P. 500 IU/L at 37C linearity....
... The stainer TST 44 is an ... needed in histology and cytology laboratories. It ... short time. Its again increased large number ... continuous working principle provides a high throughput. ...
Medicine Products: